Skip to search formSkip to main contentSkip to account menu

cantuzumab mertansine

Known as: Immunoglobulin G1, Anti-(Mucin CanAg) (Human-Mouse Monoclonal C242 Heavy Chain), Disulfide with Human-Mouse Monoclonal C242 Light Chain, Dimer, Compound with N(Sup 2')-Deacetyl-N(Sup 2')-(3-Mercapto-1-Oxopropyl)Maytansine (1:4) 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (2)

Antibodies, Monoclonal, HumanizedMaytansine

Narrower (2)

SB-408075huC242-DM1
analogs & derivativesantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy.
Nano-prodrugs usually involve a multistep synthesis which largely compromises their benefits. Here, a smart nano-prodrug platform… 
2017
2017
ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma…
10537Background: Lorvotuzumab mertansine (IMGN901; LM) is an antibody-drug conjugate, linking anti-mitotic agent (DM1) to an anti… 
2013
2013
Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine
CD56, also known as neural cell adhesion molecule (NCAM), is a type 1 transmembrane glycoprotein that is expressed on neuronal… 
2012
2012
Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma…
Abstract 728 Background: LM, an antibody-drug conjugate (ADC), is designed to specifically kill CD56+ cancer cells and contains… 
Review
2011
Review
2011
Immunoconjugates Against Solid Tumors: Mind the Gap
The objective of immunoconjugate development is to combine the specificity of immunoglobulins with the efficacy of cytotoxic… 
2011
2011
Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.
e13582 Background: Lorvotuzumab mertansine is a conjugate of the cytotoxic maytansinoid, DM1, and the CD56-binding antibody… 
Review
2011
Review
2011
Benlysta makes history
volume 29 number 4 april 2011 nature biotechnology Another cancer-killing conjugate is ImmunoGen’s IMGN901 (lorvotuzumab… 
Review
2011
Review
2011
Open access consortium
volume 29 number 4 april 2011 nature biotechnology Another cancer-killing conjugate is ImmunoGen’s IMGN901 (lorvotuzumab… 
2010
2010
Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis
Abstract 1962 Background: Lorvotuzumab mertansine, also known as IMGN901 (huN901-DM1/BB-10901) is a novel anticancer agent… 
1999
1999
Cognitive and Physiological Performance of Soldiers While Carrying Loads Over Various Terrains
Abstract : This study examined the cognitive and physiological performance of soldiers as they carried loads over various… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)